Towards a non-living vaccine for shigellosis

Shigellosis is an acute invasive enteric infection caused by Shigella spp. with an incidence of 165 millions episodes leading to 1.1 millions deaths. Considering bacteria easily spread from person to person and the emergence of multidrug- resistant Shigella strains, WHO gave high priority for the de...

Full description

Bibliographic Details
Main Authors: Camacho, A.I. (A.I.), Irache, J.M. (Juan Manuel), Gamazo, C. (Carlos)
Format: info:eu-repo/semantics/doctoralThesis
Language:eng
spa
Published: Servicio de Publicaciones de la Universidad de Navarra 2015
Subjects:
Online Access:https://hdl.handle.net/10171/38071
_version_ 1793400456884518912
author Camacho, A.I. (A.I.)
Irache, J.M. (Juan Manuel)
Gamazo, C. (Carlos)
author_facet Camacho, A.I. (A.I.)
Irache, J.M. (Juan Manuel)
Gamazo, C. (Carlos)
author_sort Camacho, A.I. (A.I.)
collection DSpace
description Shigellosis is an acute invasive enteric infection caused by Shigella spp. with an incidence of 165 millions episodes leading to 1.1 millions deaths. Considering bacteria easily spread from person to person and the emergence of multidrug- resistant Shigella strains, WHO gave high priority for the development of a shigellosis vaccine in 1991. Unfortunately, none of the proposals have an acceptable success. On this context, our proposal is based of the employment of an acellular vaccine for mucosal administration, containing relevant antigens from Shigella. Moreover, in order to increase its efficacy, it was propose the use of nanoparticles as adjuvants. Considering pathogenesis of Shigella, we select outer membrane vesicles (OMVs) as the subcellular extract. Since they are part of the outer membrane of bacteria, OMV extraction seems to be a effective strategy for isolation of the most relevant antigens of bacteria. Nevertheless, safety of this kind of subcellular vaccines is usually hampered with a lower inherent immunogenicity. Consequently, in order to obtain an adequate immune response and obtain a delivery system that allow mucosal administration, the antigenic extract from Shigella would be encapsulated in Gantrez® AN, a copolymer of ether and maleic anhydride (PMV/MA) with bioadhesive properties.
format info:eu-repo/semantics/doctoralThesis
id oai:dadun.unav.edu:10171-38071
institution Universidad de Navarra
language eng
spa
publishDate 2015
publisher Servicio de Publicaciones de la Universidad de Navarra
record_format dspace
spelling oai:dadun.unav.edu:10171-380712020-03-03T13:44:33Z Towards a non-living vaccine for shigellosis Camacho, A.I. (A.I.) Irache, J.M. (Juan Manuel) Gamazo, C. (Carlos) Vacunas Microbiología Materias Investigacion::Farmacia Shigellosis is an acute invasive enteric infection caused by Shigella spp. with an incidence of 165 millions episodes leading to 1.1 millions deaths. Considering bacteria easily spread from person to person and the emergence of multidrug- resistant Shigella strains, WHO gave high priority for the development of a shigellosis vaccine in 1991. Unfortunately, none of the proposals have an acceptable success. On this context, our proposal is based of the employment of an acellular vaccine for mucosal administration, containing relevant antigens from Shigella. Moreover, in order to increase its efficacy, it was propose the use of nanoparticles as adjuvants. Considering pathogenesis of Shigella, we select outer membrane vesicles (OMVs) as the subcellular extract. Since they are part of the outer membrane of bacteria, OMV extraction seems to be a effective strategy for isolation of the most relevant antigens of bacteria. Nevertheless, safety of this kind of subcellular vaccines is usually hampered with a lower inherent immunogenicity. Consequently, in order to obtain an adequate immune response and obtain a delivery system that allow mucosal administration, the antigenic extract from Shigella would be encapsulated in Gantrez® AN, a copolymer of ether and maleic anhydride (PMV/MA) with bioadhesive properties. 2015-04-17T10:35:11Z 2015-04-17T10:35:11Z 2015 2012-11-28 info:eu-repo/semantics/doctoralThesis https://hdl.handle.net/10171/38071 eng spa info:eu-repo/semantics/openAccess application/pdf Servicio de Publicaciones de la Universidad de Navarra
spellingShingle Vacunas
Microbiología
Materias Investigacion::Farmacia
Camacho, A.I. (A.I.)
Irache, J.M. (Juan Manuel)
Gamazo, C. (Carlos)
Towards a non-living vaccine for shigellosis
title Towards a non-living vaccine for shigellosis
title_full Towards a non-living vaccine for shigellosis
title_fullStr Towards a non-living vaccine for shigellosis
title_full_unstemmed Towards a non-living vaccine for shigellosis
title_short Towards a non-living vaccine for shigellosis
title_sort towards a non-living vaccine for shigellosis
topic Vacunas
Microbiología
Materias Investigacion::Farmacia
url https://hdl.handle.net/10171/38071
work_keys_str_mv AT camachoaiai towardsanonlivingvaccineforshigellosis
AT irachejmjuanmanuel towardsanonlivingvaccineforshigellosis
AT gamazoccarlos towardsanonlivingvaccineforshigellosis